Brief: Almirall And Kaken Pharmaceutical Enter Into Agreement For European Rights To Topical Formulation Of Efinaconazole
01/07/2021 07:32
July 1 (Reuters) - Almirall SA ALM.MC :
* ALMIRALL AND KAKEN PHARMACEUTICAL ENTER INTO A LICENSE AND
DISTRIBUTION AGREEMENT FOR EUROPEAN RIGHTS TO THE TOPICAL
FORMULATION OF EFINACONAZOLE
* KAKEN PHARMACEUTICAL GRANTS CO THE EXCLUSIVE RIGHT FOR THE
DEVELOPMENT AND COMMERCIALIZATION OF THE TOPICAL FORMULATION
EFINACONAZOLE IN EUROPE
* UNDER AGREEMENT, KAKEN PHARMACEUTICAL RECEIVES UPFRONT
CASH
PAYMENT AND HAS POTENTIAL TO RECEIVE MILESTONE PAYMENTS AND
ROYALTIES ON NET SALES OF PRODUCT
* PLANS TO HAVE A PRE-SUBMISSION MEETING WITH REGULATORY
AUTHORITIES TO PREPARE APPROVAL OF PRODUCT IN EUROPE WITHIN NEXT
12 MONTHS
* TRIAZOLE ANTIFUNGAL COMPOUND DISCOVERED BY KAKEN
PHARMACEUTICAL
IS INDICATED FOR TREATMENT OF ONYCHOMYCOSIS, FUNGAL INFECTION
OF NAIL
Source text for Eikon: ID:nCNM5zxDSl
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))